biotech
Bio-AnalystSupplement research
person

Riboflavin

Selected research topic

Immune and respiratory health

Some publications still need interpretation checks and are kept separate from the findings below.

Publications for this topic
2
Human comparison publications
0
Publications needing review
2

This result is held for interpretation. That does not mean research found no effect.

Outcome groups needing additional review (4)
  • IL-1β · Distinct papers needing additional review: 1Evidence criteria check: 1
  • IL-6 · Distinct papers needing additional review: 1Evidence criteria check: 1
  • respiratory sensitiser · Distinct papers needing additional review: 1Evidence criteria check: 1
  • TNF-α · Distinct papers needing additional review: 1Evidence criteria check: 1

One paper can appear under multiple measured outcomes or review reasons, so these counts should not be added together.

Representative outcome and study details

Some findings are held for review

Some papers have not cleared source or result review, so their findings are not summarized yet.

No confirmed result is available to summarize with study conditions.

1 publications linked to this result (1 awaiting review included)

  • Those papers are not summarized until review is complete.
Data coverage and detailed study classifications

Paper counts are separated by research topic below. One paper may contribute to multiple findings.

Analysis status: Public-ready

Ingredient analysis date:

How the grade was determined: C

The 13.6 evidence score includes 0 independent human studies and 0 clinical studies in the representative benefit area. The C tier remains conservative because of limited repetition across independent human clinical studies, too few clinical findings with an explicit effect direction.

The grade is based mainly on the research area with the most evidence. It does not mean the same result was found in other areas.

Papers linked to this ingredient overall: 130

Papers linked to this topic 2 · distinct papers 2 · comparison findings need further review · papers needing additional review 2

A publication may appear in more than one count. These numbers should not be added. Ingredient-wide papers, topic-linked papers, and sources in outcome groups use different scopes. Adding source counts may count the same paper more than once.

  • IL-1β: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
  • IL-6: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
  • respiratory sensitiser: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
  • TNF-α: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0

What the research found

IL-1β

The study needs further checking before its result can be interpreted.

Animal study · indirect · Single ingredient · General population

This finding comes from animal or cell research. It does not establish the same effect in people.

The comparison could not be confirmed.

Analysis coverage and paper counts

1 paper · 1 measured outcome

1 papers held from direction counts

Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.

IL-6

The study needs further checking before its result can be interpreted.

Animal study · indirect · Single ingredient · General population

This finding comes from animal or cell research. It does not establish the same effect in people.

The comparison could not be confirmed.

Analysis coverage and paper counts

1 paper · 1 measured outcome

1 papers held from direction counts

Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.

respiratory sensitiser

The study needs further checking before its result can be interpreted.

Animal study · indirect · Unknown intervention · Unspecified population

This finding comes from animal or cell research. It does not establish the same effect in people.

The comparison could not be confirmed.

Analysis coverage and paper counts

1 paper · 1 measured outcome

1 papers held from direction counts

Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.

TNF-α

The study needs further checking before its result can be interpreted.

Animal study · indirect · Single ingredient · General population

This finding comes from animal or cell research. It does not establish the same effect in people.

The comparison could not be confirmed.

Analysis coverage and paper counts

1 paper · 1 measured outcome

1 papers held from direction counts

Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.

How to read research findings

How should I read research findings?

Research guides

Side effects and combination findings

Findings from this ingredient alone are shown separately from those involving another supplement or medication.

No reviewed caution rules are available yet. Reported caution findings are shown below.

Findings to review with care

Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.

Side effects reported with this ingredient alone

Symptoms or adverse events reported in studies without another active ingredient.

apoptosis1 papers
Riboflavin deficiency is associated with adverse outcomes including growth retardation, increased mortality, liver damage, and apoptosis via mechanisms such as mitochondrial dysfunction, ER stress, ROS, and lipotoxicity.Human studies · Systematic review
adverse events1 papers
Vitamin B2 400 mg/day resulted in significantly fewer side effects (weight gain, dizziness, GI problems) compared to sodium valproate 500 mg/day in migraine patients (p = 0.005).Human studies · Randomized controlled trial